Design Therapeutics Inc (DSGN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $670.46M
Last updated: Nov 17, 2026 at 4:33 PM ET
Design Therapeutics Inc (DSGN) Statistics
Design Therapeutics (DSGN) has a market cap of $670.46M and an enterprise value of $655.21M. Revenue fell 100.00% over the last 12 months from the 12 months before. Its share count is up 10.68% from a year earlier.
Total Valuation
Enterprise value is 2.27% below the market cap, as cash exceeds debt.
| Market Cap | $670.46M |
|---|---|
| Enterprise Value | $655.21M |
| Latest price (Nov 17, 2026) | $9.84 |
Key Dates
The next earnings report is expected on Mar 8, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 8, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 4, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is up 33.51% over 52 weeks and trades 14.29% below its 50-day average.
| Beta (1Y) | 1.33 |
|---|---|
| 52-Week Change | +33.51% |
| 1-Month Change | -7.52% |
| 3-Month Change | -38.27% |
| 6-Month Change | -6.20% |
| 5-Year Change | -31.89% |
| Total Return (1Y) | +33.51% |
| Total Return (3Y CAGR) | +64.25% |
| Total Return (5Y CAGR) | -14.09% |
| Return vs SPY (1Y) | +18.09% |
| Max Drawdown (1Y) | -39.34% |
| Max Drawdown (3Y) | -62.80% |
| Sharpe Ratio (1Y) | 0.37 |
| Correlation with SPY (1Y) | 0.26 |
| 50-Day Average | $11.48 |
| 200-Day Average | $12.18 |
| 52-Week Range | $7.25 to $17.25 |
| RSI (14 Days) | 39.6 |
| Average Volume (20 Days) | 345.65K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 16.78x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 16.78x |
|---|---|
| Quick Ratio | 16.78x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -36.64% over the last 12 months, against a 5-year average of -21.21%.
| Return on Equity (ROE) | -36.64% |
|---|---|
| Return on Assets (ROA) | -34.17% |
| ROE (5Y Average) | -21.21% |
| ROA (5Y Average) | -20.25% |
| ROIC (5Y Average) | -29.54% |
Scores
DSGN has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 1 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Gross Profit | $14.74M |
| Operating Income | -$82.28M |
| Pretax Income | -$74.09M |
| Net Income | -$74.09M |
| Reported EPS (TTM) | -$1.20 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 93.26% of the $216.81M in total assets.
| Cash and Equivalents | $15.25M |
|---|---|
| Total Debt | $0 |
| Net Cash | $15.25M |
| Net Cash Per Share | $0.24 |
| Working Capital | $201.21M |
| Shareholder Equity | $202.20M |
| Book Value Per Share | $3.21 |
| Total Assets | $216.81M |
| Total Liabilities | $14.61M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $70.00K of capital spending, operating cash flow left -$59.37M of free cash flow.
| Operating Cash Flow | -$59.30M |
|---|---|
| Capital Expenditures | $70.00K |
| Free Cash Flow | -$59.37M |
| FCF Per Share | -$0.95 |
| Depreciation and Amortization | $1.29M |
Trailing 12 months through Sep 30, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | -13.42% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | -13.42% |
Dividends and Yields
DSGN does not pay a dividend. Its free cash flow yield is -9.57%.
| FCF Yield | -9.57% |
|---|---|
| Buyback Yield | -10.12% |
| Shareholder Yield | -10.12% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About DSGN
What is DSGN's market cap?
Design Therapeutics has a market cap of $670.46M. Its enterprise value, which adds debt and subtracts cash, is $655.21M.
How many shares of DSGN are outstanding?
Design Therapeutics has 63.04M shares outstanding. The count is up 10.68% from a year earlier.
Does DSGN pay a dividend?
No. Design Therapeutics does not pay a dividend.
How much debt does DSGN have?
Design Therapeutics has $0 of total debt and $15.25M of cash and equivalents, a net cash position of $15.25M.
DSGN pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors